Drug Search Results
More Filters [+]


Alternative Names: sulfamethizole, proklar, thiosulfil, microsul
Latest Update: 2021-04-06
Latest Update Note: Clinical Trial Update

Product Description

Sulfamethizole is a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial property. Sulfamethizole competes with PABA for the bacterial enzyme dihydropteroate synthase, thereby preventing the incorporation of PABA into dihydrofolic acid, the immediate precursor of folic acid. This leads to an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, ultimately resulting in cell growth arrest and cell death. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Sulfamethizole)

Mechanisms of Action: Dihydropteroate synthase Inhibitor,CYP2C9 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Canada | Indonesia | Ireland | Italy | Peru | South Africa | Spain | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sulfamethizole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events